Agios Pharma AI Stock Analysis
Want to see AGIO full AI Analyst Report?
Agios Pharma (AGIO) AI Stock Analysis
Agios Pharma
(NASDAQ:AGIO)
AGIO scores moderately due to a strong balance sheet, accelerating revenue, and a notably constructive earnings-call outlook (launch traction, pipeline progress, expense discipline, and clear profitability targets). The score is held back by substantial ongoing losses and heavy negative free cash flow, alongside weak price trend signals (below key moving averages with negative MACD).
Agios Pharma (AGIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.06M
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 1.64
- Revenue Growth
- 214.44%
- EPS Growth
- 9.13%
- Country
- US
- Employees
- 540
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Agios Pharma Business Overview & Revenue Model
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a med...
How the Company Makes Money
Agios makes money primarily through (1) net product revenue from sales of its approved medicines and (2) collaboration and license-related income (such as upfront payments, milestone payments, and royalties) from partners, when applicable. Product re...
Agios Pharma Earnings Call Summary
The call was strongly positive overall. Agios reported record revenue, rapid AQVESME launch adoption, 75% six-month persistence, international growth, a strong cash position, readiness for a potential sickle cell launch, and encouraging pipeline data. The main challenges were the three-month FDA review extension and uncertainty around a potential REMS, along with higher SG&A, a continuing net loss, and a planned one-time headcount reduction charge.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Agios said full year operating expenses are expected to remain approximately flat versus 2025 excluding the $25 million upfront payment associated with the cevidoplenib in licensing and an approximately $11 million onetime expense associated with the headcount reduction to be recognized in the fourth quarter; over the course of 2026, R&D headcount will have reduced by more than 35 percent compared with 2025, or more than 100 roles, with associated cost savings expected to be realized in 2027, and the company is targeting non GAAP profitability in 2028, including the potential launch of sickle cell in 2027. Agios plans to initiate a phase 3 program for AG-236 in polycythemia vera by year end, a phase 3 trial for cevidoplenib in immune thrombocytopenia in the first half of 28, and expects Phase 1b proof-of-concept data for AG-181 before the end of the year; it also expects Phase 2/3 initiation for AG-236 by the end of this year, with every-6-month dosing as the goal of Phase 2, and described 177 prescriptions as probably the more run rate for AQVESME as it continues to penetrate the thalassemia markets.
Agios Pharma Financial Statement Overview
Summary
Mixed fundamentals: strong revenue acceleration and very high gross margin (~92%), supported by a low-leverage balance sheet (debt-to-equity ~0.03). However, profitability is deeply negative (TTM net margin ~-265%) and cash burn is heavy (TTM operating cash flow about -$331.7M; free cash flow about -$336.0M), which meaningfully offsets the strengths.
Income Statement
34NegativeBalance Sheet
78PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.84M | 54.03M | 36.50M | 26.82M | 14.24M | 0 |
| Gross Profit | 129.50M | 42.51M | 32.33M | 17.32M | 12.54M | -18.78M |
| EBITDA | -378.33M | -408.62M | 723.62M | -345.46M | -223.24M | -347.27M |
| Net Income | -372.90M | -412.78M | 673.73M | -352.09M | -231.80M | 1.60B |
Balance Sheet | ||||||
| Total Assets | 1.06B | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B |
| Cash, Cash Equivalents and Short-Term Investments | 630.01M | 854.42M | 893.71M | 776.93M | 783.12M | 1.02B |
| Total Debt | 26.53M | 40.21M | 56.99M | 72.00M | 85.66M | 97.09M |
| Total Liabilities | 84.70M | 104.11M | 122.24M | 126.10M | 137.90M | 145.76M |
| Stockholders Equity | 979.34M | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | -335.97M | -377.29M | -391.53M | -297.06M | -314.36M | -413.06M |
| Operating Cash Flow | -331.68M | -372.98M | -389.84M | -296.06M | -309.48M | -407.32M |
| Investing Cash Flow | 355.56M | 377.18M | 363.44M | 239.57M | 243.26M | 1.25B |
| Financing Cash Flow | 11.97M | 8.68M | 14.44M | 5.43M | 2.35M | -765.77M |
Agios Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGIO, the sentiment is Negative. The current price of 30.15 is below the 20-day moving average (MA) of 33.42, below the 50-day MA of 33.03, and below the 200-day MA of 31.86, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 64.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AGIO.
Agios Pharma Risk Analysis
Agios Pharma disclosed 54 risk factors in its most recent earnings report. Agios Pharma reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAgios Pharma Peers Comparison
Overall Rating
NRIX61Neutral
AGIO55Neutral
IOVA51Neutral
NTLA49Neutral
RARE48Neutral
BEAM42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $1.61B | 5.92 | 49.34% | ― | 738.76% | ― | |
| 55Neutral | $1.80B | -4.84 | -34.63% | ― | 214.44% | 9.13% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $3.49B | -14.24 | -29.71% | ― | 51.31% | 56.78% | |
| 49Neutral | $1.38B | -2.91 | -64.73% | ― | -8.07% | 21.55% | |
| 48Neutral | $1.62B | -3.08 | 213.22% | ― | 15.76% | 12.63% | |
| 42Neutral | $2.17B | -20.91 | -9.69% | ― | 163.27% | 77.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals | 30.15 | 7.81 | 34.96% | |
| RARE | Ultragenyx Pharmaceutical, Inc. | 15.90 | -15.96 | -50.09% | |
| IOVA | Iovance Biotherapeutics | 7.55 | 5.29 | 234.07% | |
| NTLA | Intellia Therapeutics Inc | 9.86 | 1.62 | 19.66% | |
| BEAM | Beam Therapeutics, Inc. | 20.94 | -0.04 | -0.19% | |
| NRIX | Nurix Therapeutics, Inc. | 14.73 | 0.40 | 2.79% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
